Search

Our recent research demonstrates that the thrombopoietin receptor agonist romiplostim effectively modifies chemotherapy-induced thrombocytopenia (CIT) in solid tumor patients, allowing a majority to resume chemotherapy

… Friday, August 10, 2018 Our recent research demonstrates that the thrombopoietin receptor agonist romiplostim effectively modifies chemotherapy-induced thrombocytopenia (CIT) in solid tumor patients, allowing a majority to resume chemotherapy. In the phase II study, which included 32 patients, 84 percent

Approaches used for research into the social lives of bacteria can also be used to explore how tumors behave and evolve.

… Thursday, May 1, 2014 Summary Approaches used for research into the social lives of bacteria can also be used to explore how tumors behave and evolve. Computational biologist Joao Xavier has spent most of his career researching how bacterial cells interact with one another and produce complex group behaviors

Jeffrey Zwicker, MD, has been named Chief of the Hematology Service at Memorial Sloan Kettering Cancer Center (MSK). He joins MSK from Harvard University Medical School, where he was an Associate Professor of Medicine, and Beth Israel Deaconess Medical Center (BIDMC), where he served as Chief of Benign Hematology in the Division of Hematology since 2017. Dr. Zwicker succeeds MSK’s Interim Hematology Service Chief, Marcel van den Brink, MD, PhD.

… Wednesday, November 30, 2022 Jeffrey Zwicker, MD ,   has been named Chief of the Hematology Service at Memorial Sloan Kettering Cancer Center (MSK). He joins MSK from Harvard University Medical School, where he was an Associate Professor of Medicine, and   Beth Israel Deaconess Medical Center (BIDMC)

In honor of Women's History Month, meet the scientific hero who helped raise money and awareness for AIDS research.

… Wednesday, March 13, 2019 Summary In honor of Women’s History Month, we’re remembering female scientists from MSK’s past who shook up cancer research. Read about Charlotte Friend and Ora Rosen . In 1981, Mathilde Krim, an immunologist at the Sloan Kettering Institute , was exploring the role of naturally

In the past 30 years, major strides have been made in translational medicine — the bridge that shepherds research findings from the lab to clinical practice. Researchers, physicians, and other specialists at Memorial Sloan Kettering Cancer Center (MSK) have played a major role in these successes, as they work together with the common goal of using their discoveries to create new treatments for people with cancer.

… Friday, August 12, 2022 In the past 30 years, major strides have been made in translational medicine — the bridge that shepherds research findings from the lab to clinical practice. Researchers, physicians, and other specialists at Memorial Sloan Kettering Cancer Center (MSK) have played a major role

The list honors health care leaders who envision a better future for all New Yorkers.

… Wednesday, December 1, 2021 Craig B. Thompson, MD , President and CEO of Memorial Sloan Kettering Cancer Center (MSK), has been named to the first AMNY Metro and PoliticsNY ’s Power Players in Health Care list. The list salutes top public officials, policymakers, hospital and health maintenance organization

Sometimes a BRCA mutation is just along for the ride, rather than driving a tumor’s development.

… Wednesday, July 10, 2019 VIDEO | 00:54 Watch: Not All BRCA Mutations Cause Patients' Cancer, Study Finds Computational biologist Barry Taylor discusses findings of a new study about BRCA genes. Video Details Summary Scientists at Memorial Sloan Kettering have discovered that BRCA1 and BRCA2 mutations

Learn more about Ken Manotti, who leads philanthropic fundraising efforts at Memorial Sloan Kettering Cancer Center, where he is a Senior Vice President and Chief Development Officer.

… Wednesday, January 1, 2020 Why did you choose philanthropy as a career? I had no plans to be in this profession. But many years ago, a mentor asked me to help with fundraising at the University of Pennsylvania. She was very patient and taught me how to raise money for good causes. Is it hard asking people

Cody Bass was diagnosed with metastatic kidney cancer when he was 17. Two years later, he has no evidence of disease, thanks to a clinical trial at MSK.

… Thursday, September 5, 2024 For most teenagers, the summer before their senior year of high school is a time to hang out with friends, work a part-time job, and start thinking about college applications. But Cody Bass spent that summer recovering from a major operation at Memorial Sloan Kettering Cancer

MSK researchers have discovered a new mechanism of resistance to KRAS inhibitors that suggests an opportunity to make the treatment more effective.

… Thursday, July 11, 2024 Mutations in the KRAS gene are the primary driver of  pancreatic cancer . A new class of drugs known as KRAS inhibitors is showing initial promise in clinical trials, but many tumors quickly develop resistance to the treatment. Now, researchers at Memorial Sloan Kettering Cancer